Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 CAR T cell therapy in pediatric r/r B-ALL
NCT06635330Phase 2Recruiting
- Sponsor
- Kara Yakhteh Tajhiz Azma
- Start
- May 2024
- Primary completion
- Sep 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of mivocabtagene autoleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Kara Yakhteh Tajhiz Azma. Started May 2024; status: recruiting.
02
Drugs
mivocabtagene autoleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06635330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06635330.